Saturday 17 October 2026
Export IMDX’s income statement to Excel — free account
Insight Molecular Diagnostics Inc.
IMDX Healthcare Diagnostics & Research
Insight Molecular Diagnostics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.1 million, up 115.6% from fiscal 2024. In the quarter to June 2026, revenue fell 53.9%, EPS fell 3.33% and free cash flow fell 54.0%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
3.01
0.05
−1.63%
Follow IMDX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Piotroski F-Score |
3 | 4 | 5 | 3 | — | — | — | — | — | — |
Altman Z-Score |
(25.63) | (19.13) | (6.24) | (3.74) | (1.33) | (0.59) | — | — | — | — |
P/S ratio |
56.37 | 16.54 | 16.80 | 39.90 | 87.79 | 128.69 | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(63.82) | (43.70) | (14.17) | (8.27) | (4.34) | (9.25) | — | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Beneish M-Score |
(7.73) | (10.57) | (2.94) | — | (0.13) | — | — | — | — | — |
P/Operating CF |
(41.22) | (5.81) | (5.71) | (3.96) | (27.31) | (25.47) | — | — | — | — |
P/B ratio |
0.00 | 0.00 | 1.23 | 1.11 | 2.96 | 4.67 | — | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.85 | — | — | — | — |
EV/Sales |
53.75 | 33.26 | 12.09 | 21.64 | 74.00 | 123.51 | — | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 3.50 | 0.00 | 0.00 | — | — | — | — |
EV/Operating CF |
(9.82) | (3.02) | (0.78) | (0.45) | (4.53) | (5.78) | — | — | — | — |
EV/FCF |
(8.59) | (2.95) | (0.76) | (0.42) | (4.26) | (5.52) | — | — | — | — |
Quick Ratio |
1.11 | 1.41 | 1.38 | 1.85 | 2.50 | 0.89 | 5.06 | 1.52 | 1.88 | 2.90 |
Current Ratio |
1.27 | 1.62 | 1.49 | 2.11 | 2.77 | 1.03 | 5.17 | 1.55 | 1.91 | 2.97 |
Net Debt/EBITDA |
(0.67) | (0.53) | 0.40 | (2.99) | 0.61 | 0.22 | 0.94 | 0.57 | 0.39 | 1.13 |
Debt/Assets |
175.28% | 114.25% | 0.00% | 2.73% | 2.22% | 2.72% | 4.78% | 5.61% | 13.30% | 2.15% |
Debt/Equity |
(1.43) | (3.27) | 0.00 | 0.08 | 0.05 | 0.05 | 0.06 | 0.16 | 0.31 | 0.03 |
Asset Turnover |
0.13 | 0.03 | 0.02 | 0.01 | 0.02 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.44 | 0.34 | 0.81 | 0.62 | 0.56 | 0.87 | 0.88 | 0.74 | 0.69 | 0.67 |
Capex/Depreciation |
(1.45) | (0.33) | 0.04 | (0.18) | (0.53) | (1.34) | (2.05) | (0.02) | (0.14) | (0.27) |
Interest Coverage |
(469.03) | (726.68) | (483.38) | (216.83) | (257.06) | (117.90) | 74.38 | (70.38) | (86.86) | (397.86) |
| 229.65% | (1,480.67%) | (104.91%) | (147.57%) | (129.88%) | (93.07%) | (130.91%) | (402.61%) | (271.64%) | (110.14%) | |
| (165.10%) | (110.32%) | (32.83%) | (56.55%) | (59.63%) | (62.83%) | (90.84%) | (159.66%) | (157.12%) | (82.18%) | |
ROIC |
(2,334.00%) | (199.01%) | (142.35%) | (67.78%) | (96.18%) | (68.34%) | (135.05%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(519.57%) | (753.48%) | (393.30%) | (332.20%) | (209.38%) | (857.16%) | (100.82%) | (426.36%) | (395.73%) | (122.60%) |
Average Days of Receivables |
101.53 | 313.00 | 117.54 | 766.58 | 238.63 | 60.93 | — | — | — | — |
Research and Development Expense of Revenue |
392.11% | 523.07% | 618.36% | 762.11% | 229.07% | 805.92% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
418.64% | 752.15% | 929.94% | 2,402.19% | 1,039.31% | 1,914.64% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.42 | 0.76 | 0.62 | 0.50 | 0.44 | 0.00 | 0.00 | 0.07 | 0.07 |
Share Based Compensation of Revenue |
54.72% | 93.20% | 183.63% | 1,048.23% | 311.24% | 416.61% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.18) | (1.14) | (1.73) | (1.05) | (0.29) | (0.08) | — | — | — | — |
Graham Number |
6.13 | 9.64 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Earnings Yield |
(21.60%) | (184.87%) | (115.28%) | (189.65%) | (32.72%) | (19.25%) | — | — | — | — |
Free Cash Flow Yield |
(11.10%) | (68.15%) | (95.27%) | (130.56%) | (19.79%) | (17.39%) | — | — | — | — |
Revenue per Share |
0.13 | 0.14 | 0.20 | 0.17 | 0.49 | 0.37 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.73) | (1.58) | (3.05) | (8.23) | (8.08) | (7.94) | (7.69) | (6.16) | (8.87) | (5.67) |
Capex per Share |
(0.10) | (0.04) | 0.01 | (0.78) | (0.51) | (0.37) | (0.36) | (0.02) | (0.06) | (0.08) |
Free Cash Flow per Share |
(0.83) | (1.62) | (3.04) | (9.01) | (8.59) | (8.31) | (8.04) | (6.17) | (8.93) | (5.75) |
Cash per Share |
0.40 | 0.66 | 1.23 | 3.69 | 7.61 | 2.39 | 8.75 | 4.47 | 5.54 | 9.36 |
Shareholders Equity per Share |
(1.03) | (0.94) | 2.68 | 6.19 | 14.67 | 10.23 | 12.02 | 1.81 | 2.92 | 7.43 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(1.03) | (0.94) | 2.68 | 6.19 | 14.67 | 10.23 | 12.02 | 1.81 | 2.92 | 7.43 |
Free Cash Flow |
(25.37) | (21.20) | (23.25) | (49.91) | (38.19) | (27.21) | (20.63) | (11.68) | (13.48) | (7.63) |
Working Capital |
3.23 | 4.48 | 3.50 | 13.43 | 25.02 | 0.23 | 18.52 | 3.08 | 4.07 | 8.42 |
Capital Expenditures |
(3.18) | (0.51) | 0.07 | (4.34) | (2.25) | (1.23) | (0.92) | (0.03) | (0.09) | (0.11) |
Net Current Asset Value |
(41.91) | (35.60) | (43.73) | (40.26) | (55.20) | (12.71) | 13.94 | 2.55 | 2.72 | 8.11 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
Capex to Sales |
0.79 | 0.27 | (0.05) | 4.53 | 1.02 | 1.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.34 | 0.44 | 0.44 | 2.76 | 0.76 | 0.28 | 0.12 | 2.08 | 0.81 | 0.56 |
Cash ROIC |
(97.60%) | (58.18%) | (77.77%) | (86.88%) | (37.22%) | (63.55%) | (37.38%) | (94.05%) | (95.43%) | (33.78%) |
Accounts Receivable Turnover |
2.96 | 1.79 | 1.20 | 0.56 | 2.68 | 1.32 | — | — | — | — |
Accounts Payable Turnover |
0.84 | 0.88 | 0.99 | 0.64 | 0.69 | 4.12 | 1.08 | 3.28 | 1.94 | 1.09 |
Inventory Turnover |
4.11 | 3.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
528.49 | 524.95 | 319.12 | 468.59 | 849.16 | 85.00 | 497.63 | 108.39 | 110.13 | 398.01 |
Days of Inventory on Hand |
92.65 | 131.16 | 0.00 | 0.00 | 142.62 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
1.37 | 1.05 | 1.25 | 1.72 | 0.82 | 0.92 | — | — | — | — |
Average Payables |
2.09 | 1.30 | 1.10 | 1.53 | 1.12 | 0.45 | 0.32 | 0.17 | 0.30 | 0.35 |
Average Inventory |
0.43 | 0.36 | — | — | — | — | — | — | — | — |
Average Assets |
30.42 | 54.99 | 87.49 | 129.83 | 107.49 | 47.64 | 24.69 | 9.87 | 12.33 | 13.59 |
Average Common Equity |
(21.87) | 4.10 | 27.38 | 49.75 | 49.35 | 32.16 | 17.13 | 3.91 | 7.13 | 10.14 |
Columns are period end dates